Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Plus Therapeutics (PSTV), a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement as of March 7, 2025. The company's common stock will maintain its listing and continue trading on The Nasdaq Capital Market.
Plus Therapeutics (PSTV), un'azienda farmaceutica in fase clinica focalizzata sullo sviluppo di radioterapie mirate per i tumori del sistema nervoso centrale, ha riacquistato con successo la conformità ai requisiti minimi di patrimonio netto degli azionisti di Nasdaq a partire dal 7 marzo 2025. Le azioni ordinarie dell'azienda manterranno la loro quotazione e continueranno a essere scambiate sul Nasdaq Capital Market.
Plus Therapeutics (PSTV), una empresa farmacéutica en etapa clínica centrada en el desarrollo de radioterapias dirigidas para los cánceres del sistema nervioso central, ha recuperado con éxito el cumplimiento del requisito de capital mínimo de accionistas de Nasdaq a partir del 7 de marzo de 2025. Las acciones ordinarias de la empresa mantendrán su cotización y continuarán negociándose en el Nasdaq Capital Market.
Plus Therapeutics (PSTV), 중앙 신경계 암을 위한 표적 방사선 치료제를 개발하는 임상 단계의 제약 회사가 2025년 3월 7일 기준으로 Nasdaq의 최소 주주 자본 요건을 성공적으로 회복했습니다. 회사의 보통주는 상장 상태를 유지하며 Nasdaq 자본 시장에서 계속 거래됩니다.
Plus Therapeutics (PSTV), une entreprise pharmaceutique en phase clinique axée sur le développement de radiothérapies ciblées pour les cancers du système nerveux central, a réussi à retrouver sa conformité avec l'exigence de capital minimum des actionnaires de Nasdaq au 7 mars 2025. Les actions ordinaires de l'entreprise conserveront leur cotation et continueront à être échangées sur le Nasdaq Capital Market.
Plus Therapeutics (PSTV), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von zielgerichteten Radiotherapeutika für Krebs des zentralen Nervensystems konzentriert, hat am 7. März 2025 erfolgreich die Einhaltung der Mindestanforderungen an das Eigenkapital der Aktionäre von Nasdaq wiedererlangt. Die Stammaktien des Unternehmens werden ihre Notierung behalten und weiterhin im Nasdaq Capital Market gehandelt.
- Maintained Nasdaq listing status, avoiding potential delisting risks
- Regained compliance with minimum stockholders' equity requirement
- None.
HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq’s minimum stockholders’ equity requirement. The Company’s common stock will continue to be listed and traded on The Nasdaq Capital Market.
About Plus Therapeutics
Headquartered in Houston, Texas, Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. For more information, visit https://plustherapeutics.com/.
About CNSide Diagnostic, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Plus Therapeutics, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide™, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide™ CSF Assay Platform enables quantitative analysis and molecular characterization of tumor cells and circulating tumor DNA in the cerebrospinal fluid that inform and improve the management of patients with leptomeningeal metastases. The Company is planning to commercialize CNSide™ in the U.S. in 2025.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements,” within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, related to the Company’s ability to comply with the continued listing requirements of Nasdaq. All statements in this press release, other than statements of historical fact are forward-looking statements. We may, in some cases use terms such as “will,” “believe,” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Results or events in future periods could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the ability of the Company to maintain compliance with Nasdaq continued listing requirements; the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it; market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; challenges associated with radiotherapeutic manufacturing, production and distribution capabilities necessary to support the Company’s clinical trials and any commercial level product demand; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. The Company discusses some of these matters more fully, as well as certain risk factors that could affect the Company’s business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements the Company makes may turn out to be wrong and can be affected by inaccurate assumptions the Company might make or by known or unknown risks, uncertainties, and other factors, including those identified in this Current Report. Accordingly, you should not place undue reliance on the forward-looking statements made in this Current Report, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Jules Abraham
Managing Director, Communications
CORE IR
Julesa@coreir.com
FAQ
What does Plus Therapeutics' Nasdaq compliance status mean for PSTV stock?
When did Plus Therapeutics (PSTV) regain Nasdaq compliance?
What Nasdaq requirement did PSTV meet to maintain listing?
What is Plus Therapeutics' main business focus?
